Virios Therapeutics EBIT

As of the most recent data (June 2026), VIRI shows a EBIT of $-16B. That compares with $-21B in the prior-year period — up 26.0% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VIRI's EBIT is now $-16B (was $-21B) — a 26.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Virios Therapeutics is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. Virios Therapeutics is at $-16B, which is lower that average. That is roughly 170.7% below the sector mean. Use the comparison chart on this page to see how VIRI stacks up against individual peers as well.

Tracking VIRI's ebit over time shows whether Virios Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-16B That compares with $-21B in the prior-year period — up 26.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Virios Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-16B) with ownership activity and broader fundamentals.